Results for inferioritetsstudie translation from Danish to English

non-inferioritetsstudie af ændring fra baseline ved sammenligning af gennemsnitligt døgn-iop (mmhg)
comparison of mean diurnal iop (mmhg) change from baseline– non-inferiority study

dette var et non-inferioritetsstudie, der var designet til at udelukke en 15 % risikostigning i tumorprogression eller død med epoetin alfa plus standardbehandling sammenlignet med standardbehandling alene.
this was a non inferiority study designed to rule out a 15% risk increase in tumour progression or death of epoetin alfa plus standard of care (soc) as compared with soc alone.

virkningen af palonosetron til forebyggelse af kemoterapifremkaldt kvalme og opkastning hos pædiatriske cancerpatienter blev vist i et andet pivotalt non-inferioritetsstudie, der sammenlignede en enkelt intravenøs infusion med palonosetron versus et regime med intravenøs ondansetron.
the efficacy of palonosetron for the prevention of chemotherapy-induced nausea and vomiting in paediatric cancer patients was demonstrated in a second non-inferiority pivotal trial comparing a single intravenous infusion of palonosetron versus an intravenous ondansetron regimen.

aloxis virkning til forebyggelse af kemoterapifremkaldt kvalme og opkastning hos pædiatriske cancerpatienter blev vist i et andet pivotalt non-inferioritetsstudie, der sammenlignede en enkelt intravenøs infusion med palonosetron versus et regime med i.v. ondansetron.
the efficacy of aloxi for the prevention of chemotherapy-induced nausea and vomiting in paediatric cancer patients was demonstrated in a second non-inferiority pivotal trial comparing a single intravenous infusion of palonosetron versus an i.v. ondansetron regimen.

candidæmi og invasiv candidiasis: micafungin (100 mg/dag eller 2 mg/kg/dag) var lige så effektiv og bedre tolereret end liposomalt amphotericin b (3 mg/kg) som førstevalgsbehandling af candidæmi og invasiv candidiasis i et randomiseret, dobbeltblindt, multinationalt non-inferioritetsstudie.
candidaemia and invasive candidiasis: micafungin (100 mg/day or 2 mg/kg/day) was as effective as and better tolerated than liposomal amphotericin b (3 mg/kg) as first-line treatment of candidaemia and invasive candidiasis in a randomised, double-blind, multinational non-inferiority study.